Androgen Receptor Targeting Drugs in Castration-Resistant Prostate Cancer and Mechanisms of Resistance

DJ Crona¹, MI Milowsky²,³ and YE Whang²,³

Reactivated androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanisms of resistance include the following: 1) Expression of AR splice variants, such as the AR-V7 isoform, which lacks the ligand-binding domain; 2) AR missense mutations in the ligand-binding domain, such as F876L and T877A; and 3) Mutation or overexpression of androgen biosynthetic enzymes or glucocorticoid receptor. Several novel agents may overcome resistance mechanisms. Galeterone acts through multiple mechanisms that include degradation of AR protein and is being evaluated in CRPC patients positive for AR-V7. EPI-001 and related compounds inhibit AR splice variants by targeting the N-terminal transactivation domain of AR. Promising therapies and novel biomarkers, such as AR-V7, may lead to improved outcomes for CRPC patients.

In the United States, prostate cancer is the most commonly diagnosed malignancy, and is the second leading cause of cancer-related death among men. It is estimated that 220,800 new cases will be diagnosed, and 27,540 deaths caused by prostate cancer will occur in 2015.¹ For over seven decades, surgical or medical androgen deprivation therapy (ADT) has been the primary treatment paradigm for men with advanced prostate cancer (PC).² Surgical ADT is achieved through bilateral orchiectomy, while medical ADT may be achieved through the use of luteinizing hormone-releasing hormone (LH-RH) agonists or LH-RH antagonists, and both surgical and medical ADT have been shown to successfully palliate symptoms associated with metastatic PC.

While surgical and medical ADT is initially effective at stabilizing or causing disease regression in most patients, their effects are transient and virtually all patients develop disease progression to a stage referred to as castration-resistant PC (CRPC). Ultimately, metastatic CRPC (mCRPC) remains incurable, and traditionally patients had been resigned to receive traditional cytotoxic chemotherapeutics, such as mitoxantrone or docetaxel. However, during the past decade the number and types of viable treatment options for patients with mCRPC have expanded to include the immunotherapeutic sipuleucel-T for asymptomatic or minimally symptomatic mCRPC patients,³ the semisynthetic taxane-derivative cabazitaxel designed to overcome docetaxel resistance,⁴ the α-emitting radiopharmaceutical radium-223 that targets bone metastases,⁵ and finally the bone-modifying agent denosumab that prevents or delays clinical sequelae associated with bone metastases.⁶ ⁷ Historically, CRPC had been considered “androgen-independent” or “hormone-refractory”; however, recent preclinical and clinical data have elucidated that CRPC remains highly dependent on the AR signaling axis in the castrate host.⁸ ⁹ The development and subsequent approval of two second-generation AR axis-targeting agents, abiraterone and enzalutamide, by the US Food and Drug Administration (FDA) have confirmed the central role of the AR signaling axis on CRPC pathophysiology.¹⁰ ¹³ While the treatment landscape for patients with CRPC has dramatically changed and now includes two approved agents that effectively target AR signaling, acquired resistance to these two agents limits treatment durability, and eventually the disease will become lethal to virtually all mCRPC patients.

The review discusses the two approved second-generation AR-targeting agents, highlights the most plausible mechanisms that lead to drug resistance in these two AR-targeting medications, and reviews the latest literature regarding novel agents in development.
Figure 1. The full-length androgen receptor compared with the AR-V7 splice variant. The AR gene is comprised of eight exons. The full-length AR protein contains the N-terminal transactivation domain (encoded in exon 1) that is critical for engaging the cellular transcription complex, the DNA binding domain (encoded in exons 2-3) that directs the binding of AR protein to specific DNA sequences, the hinge region (encoded in exon 4) encoding the nuclear translocation signal, and the ligand-binding domain (encoded in exons 5–8) that binds the androgen ligands. The AR-V7 splice variant is produced by alternate splicing of the AR gene that leads to the addition of cryptic exon 3. This leads to premature termination of the AR protein, which results in the loss of the hinge region and LBD and the formation of a truncated androgen receptor. AR-V7 is constitutively localized to the nucleus and binds DNA and promotes transcription of target genes without the need for androgen ligands. Therefore, AR-V7 is not inhibited by agents such as abiraterone or enzalutamide that target the ligand-binding domain of AR. Each number represents the corresponding exon in the AR. Abbreviations: AR-FL, full length androgen receptor; AR-V7, androgen receptor splice variant V7; CE3, cryptic exon 3; DBD, DNA binding domain; LBD, ligand-binding domain; NTD, N-terminal transactivation domain.

that may overcome these resistance mechanisms related to the AR signaling axis (e.g., galeterone and EPI-001).

THE ROLE OF AR IN PROSTATE CANCER

The human AR is a 110 kD protein comprised of ~919 amino acids that is encoded by the AR gene (AR). AR is more than 90 kb long, is comprised of eight exons, and is located on the X chromosome at Xq11-12. The AR protein contains several functional domains that include the N-terminal transactivation domain (NTD) that is critical for engaging the cellular transcription complex, the DNA-binding domain (DBD) that directs the binding of AR protein to specific DNA sequences, the hinge region encoding the nuclear translocation signal, and the ligand-binding domain (LBD) that binds the androgen ligands. The NTD is encoded in exon 1, the DBD is encoded in exons 2 and 3, the hinge region is encoded in exon 4, and the LBD is encoded in exons 5–8 (Figure 1).14

The AR is a ligand-dependent transcription factor that is part of the nuclear receptor superfamily. Its primary role is to respond to androgenic steroid hormones, such as testosterone and dihydrotestosterone (DHT). In the absence of one of these androgenic ligands, the AR is sequestered in the cytoplasm bound to chaperone proteins (e.g., HSP90) where it is inactive, yet in a conformation that possesses high affinity for ligand binding.15 Upon androgen binding to the LBD of the AR, the receptor dissociates from the chaperone complex, and then translocates into the nucleus where it dimerizes with a second AR and binds to androgen response elements in cis-regulatory regions to regulate transcription of androgen-dependent target genes (e.g., KLK3, which encodes for prostate-specific antigen (PSA)) (Figure 2).15,16 Transcriptional regulation of these target genes, through persistent AR signaling, contributes to PC proliferation and survival.

ADT is initially effective in the majority of PC patients through suppression of gonadal testosterone production. Reduction of circulating serum testosterone to castrate levels ultimately renders the AR transcriptionally inactive. As a result, the AR no longer activates androgen-dependent target genes that drive PC viability and proliferation. However, in the context of metastatic PC, the positive effects of ADT on AR signaling are temporary, and patients progress on ADT within ~18–30 months.17 Reactivation of the AR ultimately leads to a CRPC phenotype in virtually all patients where serum PSA levels rise and/or there is evidence of disease progression, despite effective suppression of testosterone below castrate levels (≤50 ng/dL). Several mechanisms have been proposed to explain how the AR is reactivated and leads to CRPC. These mechanisms include: 1) AR gene overexpression (with or without gene amplification) that results in the increased protein level and hypersensitization to low concentrations of androgens; 2) AR point mutations that lead to promiscuous activation of AR in response to atypical ligands such as adrenal androgens, other steroid hormones, or antiandrogen drugs; 3) de novo intratumoral synthesis of androgens; and 4) expression of constitutively active AR splice variants that lack the LBD.18,19

NEXT-GENERATION AR-TARGETING AGENTS

Antiandrogen agents have been developed to inhibit DHT and testosterone binding to the AR, thus diminishing the ability of the AR to exert transcriptional control over target genes responsible for PC viability and proliferation. First-generation antiandrogen medications (e.g., bicalutamide, flutamide, and nilutamide) competitively inhibit androgenic ligands (e.g., testosterone and DHT) from binding to the AR. In the context of advanced CRPC, these agents provide only modest, temporary clinical benefit.20 Bicalutamide (the most commonly used first-generation antiandrogen) monotherapy is inferior to ADT,21 and part of a combined androgen blockade (CAB) paradigm, a meta-analysis of CAB trials revealed only a modest survival benefit (~2% at 5 years).22 Moreover, at the molecular level, first-generation antiandrogens have actually been shown to have AR agonist activity in CRPC cells where AR protein has been overexpressed.23,24 In response to the knowledge that CRPC remains dependent on androgens and AR signaling, as well as the shortcomings of first-generation antiandrogens, two second-generation AR-targeting agents have been recently approved by the FDA for the treatment of mCRPC patients.

Abiraterone acetate (the prodrug of abiraterone) is a selective, irreversible inhibitor of intratumoral androgen biosynthesis by potently blocking the cytochrome P450 CYP17A1. CYP17A1 is an enzyme with 17α-hydroxylase and C17,20-lyase activity central to androgen biosynthesis, and is key in the conversion of pregnenolone to dehydroepiandrosterone (DHEA) (Figure 2).25 DHEA is an important upstream precursor of DHT and testosterone, and thus inhibiting its production correspondingly reduces the amount of ligand available to stimulate AR signaling. Preclinically, abiraterone has been shown to be a potent
inhibitor of both 17α-hydroxylase and C17,20-lyase.26 Results of an open-label observational study of 57 mCRPC patients revealed that abiraterone is capable of achieving sustained suppression of both circulating testosterone and testosterone in bone marrow aspirates infiltrated with metastatic tumor cells.27 Results from several phase I/II trials demonstrated that abiraterone is effective and safe with or without corticosteroids (although symptoms associated with secondary mineralocorticoid excess were higher in patients not concomitantly administered a corticosteroid), that there was a ≥50% PSA decline in the majority of patients, and that abiraterone was efficacious in men with mCRPC who had prior exposure to ketoconazole (a weak CYP17A1 inhibitor).28–31 Based on results from these phase I/II trials, the double-blinded, placebo-controlled phase III COU-AA-301 trial was conducted in men with mCRPC who had previously been treated with chemotherapy (n = 1,195).10 The primary endpoint for COU-AA-301 was overall survival (OS). In the abiraterone-treated patients, there was a 35% reduction in the risk of death (hazard ratio (HR), 0.65; 95% confidence interval (CI), 0.54 to 0.77; P < 0.001) with a 3.9-month increased median OS, when compared to placebo (14.8 vs. 10.9 months). Abiraterone was also shown to be superior to placebo for all secondary endpoints, including: radiographic progression-free survival (PFS), time to PSA progression, and PSA response rate. Mineralocorticoid-related adverse events (e.g., fluid retention, hypertension, and hypokalemia) were more common among patients treated with abiraterone. Based on the COU-AA-301 results, in 2011 the FDA approved abiraterone as a second-line treatment option for mCRPC patients after traditional cytotoxic chemotherapy with docetaxel. A second randomized, double-blinded, placebo-controlled phase III trial (COU-AA-302) was conducted in chemotherapy-naïve mCRPC patients (n = 1088).11 The co-primary endpoints for COU-AA-302 were OS and radiographic PFS. In the abiraterone-treated patients, there was a 25% reduction in the risk of death (HR, 0.75; 95% CI, 0.61 to 0.93; P = 0.01) and a 47% reduced risk of progression in patients treated with abiraterone (HR, 0.53; 95% CI, 0.45 to 0.62; P < 0.001), with an 8.3-month increased median PFS (16.5 vs. 8.2 months), when compared to placebo. Abiraterone also showed superiority among all secondary endpoints, including: time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, PSA progression, and decline in performance status. Again, mineralocorticoid-mediated toxicities were significantly more common among the patients treated with abiraterone. In the updated final analysis of COU-AA-302, the abiraterone-treated patients demonstrated a statistically significant improvement in OS (34.7 vs. 30.3 months in the placebo group).32 Based on the COU-AA-302 results, in 2012 the FDA approved abiraterone as a first-line treatment option for mCRPC.

Enzalutamide (formerly known as MDV3100) was developed to overcome the resistance to first-generation androgen receptor-blocking agents. Unlike first-generation androgens, enzalutamide has been shown to be a pure antagonist without also possessing agonist characteristics in prostate cancer cells with overexpressed AR.33 Enzalutamide binds to the AR LBD and more potently antagonizes the receptor than first-generation antiandrogens. It also inhibits AR complex-mediated transcription by preventing AR translocation into the cell nucleus, recruitment of AR coregulators, and binding to DNA (Figure 2). Results from a phase I/II trial of patients with progressive mCRPC (n = 140) demonstrated several antitumor effects at all doses investigated.34 Investigators noted a ≥50% PSA decline and stabilized bone disease in
56% of patients, decreased circulating tumor cells (CTCs) in 40%, and responses in soft-tissue disease in 22% of patients. PSA declines were dose-dependent from 30–150 mg, but plateaued between 150–240 mg. Additionally, another phase II trial of enzalutamide-treated mCRPC patients (n = 60) provided the first clinical data supporting the hypothesis that the therapeutic benefit of enzalutamide can be attributed to AR inhibition manifested by relocation of the nuclear AR to the cytoplasm. Based on results from the original phase I/II trial, the double-blinded, placebo-controlled phase III AFFIRM trial was conducted in men with mCRPC who had previously been treated with chemotherapy (n = 1,199). The primary endpoint of AFFIRM was OS. For patients treated with enzalutamide, the median OS was 4.8 months longer (18.4 vs. 13.6 months), and the risk of death was decreased by 37%, when compared to placebo (HR, 0.63; 95% CI, 0.53 to 0.75; P < 0.001). Enzalutamide was also shown to be superior with regard to all secondary endpoints, including: radiographic PFS time, the proportion of patients with a ≥50% PSA reduction, time to PSA progression, soft-tissue and quality of life response rates, and time to first skeletal-related event (SRE). Based on the AFFIRM results, in 2012 the FDA approved enzalutamide as a second-line treatment option for mCRPC patients after they received docetaxel. A second randomized, double-blinded, placebo-controlled phase III trial was conducted in chemotherapy-naïve mCRPC patients (n = 1,717). The co-primary endpoints for the PREVAIL study were OS and radiographic PFS. In the enzalutamide-treated patients, there was a 29% reduction in the risk of death (HR, 0.71; 95% CI, 0.60 to 0.84; P < 0.001) with a 2.2-month increased median OS, when compared to placebo (32.4 vs. 30.2 months). The rate of radiographic PFS at 12 months was also higher in enzalutamide-treated patients, when compared to placebo (65% vs. 14%), with an 81% reduced risk of progression (HR, 0.19; 95% CI 0.15 to 0.23; P < 0.001). Enzalutamide also showed superiority among all secondary endpoints, including: time to initiation of cytotoxic chemotherapy, time to first SRE, rate of a complete or partial soft-tissue response, time to PSA progression, and a rate of decline of at least 50% in PSA. Based on the PREVAIL results, in 2014 the FDA approved enzalutamide as a first-line treatment option for mCRPC.

Combined, these studies provide evidence that both enzalutamide and abiraterone are clinically effective by suppressing the reactivated AR signaling axis, which is central to CRPC pathophysiology and progression.

MECHANISMS OF RESISTANCE TO APPROVED AR-DIRECTED DRUGS

Although abiraterone and enzalutamide represent a major conceptual and clinical advancement in the treatment of mCRPC, ~20–40% of patients present with primary resistance to these agents (e.g., no initial PSA response). But perhaps just as important, patients who experience an initial PSA response after treatment with either abiraterone or enzalutamide will eventually develop secondary resistance to the drug. Despite distinct mechanisms by which AR signaling is inhibited, there may be cross-resistance between these two drugs. This suggests a possibility that there may be a common mechanism of resistance and limits the clinical options for patients with progressive disease on abiraterone or enzalutamide. However, other negative prognostic features (e.g., more advanced disease, greater tumor burden, and more symptoms) were observed more frequently in enzalutamide-refractory patients who received abiraterone, when compared to the original phase III abiraterone trial, and could conceivably account for the modest response and a shorter PFS that was observed. Therefore, cross-resistance mechanisms of abiraterone and enzalutamide require additional preclinical and clinical validation.

While multiple mechanisms of acquired resistance to enzalutamide and abiraterone have been proposed, substantial clinical evidence has emerged for the role of AR splice variants (AR-Vs) as mediators of resistance to abiraterone and enzalutamide. AR-Vs are commonly truncated versions of the AR, and have lost their C-terminal LBD due to alternative splicing of AR mRNA. Over 20 AR-V isoforms have been identified in vitro in cell lines and most AR-V mRNA species retain exons 1–3, which encode the AR NTD and DBD domains. In many AR-Vs, aberrant splicing of the AR mRNA leads to the addition of one of small “cryptic exons” after exon 3 and premature termination of the AR protein. For example, AR splice variant-7 (AR-V7) contains cryptic exon 3 (Figure 1). As a result of the loss of the C-terminal LBD, AR-Vs are constitutively active without androgenic ligands present and localize to the nucleus and promote transcription of target genes. AR-V7 has emerged as a putative variant that underlies clinical resistance to enzalutamide and abiraterone. In preclinical xenograft models, it was shown that abiraterone and enzalutamide induced AR-V7 expression. A recent CTC assay, capable of detecting AR-V7 mRNA expression, was used to prospectively evaluate AR-V7 in mCRPC patients treated with either enzalutamide or abiraterone (n = 62). In that study, 31% of the enzalutamide-treated patients and 19% of the abiraterone-treated patients had detectable AR-V7 in CTCs. Among the enzalutamide-treated patients, AR-V7-positive patients experienced significantly lower PSA response rates (0% vs. 53%, P = 0.004), and achieved significantly shorter OS (median 5.5 months vs. not reached, P = 0.002), PSA PFS (median 1.4 vs. 6.0 months, P < 0.001), and radiographic PFS (median 2.1 vs. 6.1 months, P < 0.001), when compared to AR-V7-negative patients. Similarly, among the abiraterone-treated patients, AR-V7-positive patients experienced significantly lower PSA response rates (0% vs. 68%, P = 0.004), and achieved significantly shorter OS (median 10.6 months vs. not reached, P = 0.006), PSA PFS (median 1.3 months vs. not reached, P < 0.001), and radiographic PFS (median 2.3 vs. not reached, P < 0.001), when compared to AR-V7-negative patients. These data suggest that for patients treated with enzalutamide and/or abiraterone, the AR-V7 is likely predictive of resistance to both agents and associated with negative clinical outcomes. While these findings require independent confirmation in a prospective cohort, they provide plausible mechanisms by which tumor cells escape from selective pressures of potent AR-targeted therapy and why cross-resistance between abiraterone and enzalutamide exists. Interestingly, serial measurements of AR-V7 revealed that some patients converted from the AR-V7-negative to the AR-V7-positive status.
with both AR-targeted therapy and cytotoxic chemotherapy. However, loss of AR-V7 expression only occurred with taxane chemotherapy. Moreover, data from a separate study suggests that patients with detectable AR-V7 in CTCs may benefit more from taxane treatment, when compared to either abiraterone or enzalutamide treatment. Among the AR-V7-positive patients, PSA responses were higher in those treated with a taxane than in patients treated with an AR-targeting agent (41% vs. 0%; \( P < 0.001 \)). In addition, PSA PFS (HR, 0.19; 95% CI, 0.07 to 0.52; \( P = 0.001 \)) and radiologic PFS (HR, 0.21; 95% CI, 0.07 to 0.59; \( P = 0.003 \)) were both significantly longer in patients treated with a taxane. Interestingly, there were no observed differences in treatment efficacy between the taxanes and AR-targeting agents among the patients with undetectable AR-V7; however, this was a small study and not sufficiently powered to detect differences in efficacy among the AR-V7-positive patients. These data suggest that the AR-V7 assay may have the potential to become a clinically useful biomarker in directing the choice of therapy for CRPC patients.

Somatic point mutations in the AR gene have been implicated as etiologies underlying resistance to first-generation AR-targeting medications. Missense mutations in the AR LBD can cause reduced specificity of binding between the AR and its ligands. These somatic point mutations allow AR activation in response to other hormones (e.g., progesterone), and can affect coregulatory recruitment. One mutation, which causes a phenylalanine to leucine substitution at amino acid 876 (F876L), has been shown to convert enzalutamide into a partial agonist in prostate cancer cell lines. Moreover, one study also showed that this point mutation occurs spontaneously in cells treated with enzalutamide, which suggests that in vivo this could be an important mechanism that explains secondary resistance to enzalutamide. In support of this idea, the F876L mutation was detected in circulating tumor DNA of patients treated with enzalutamide or ARN-509, a novel AR antagonist similar to enzalutamide. Another mutation, which causes a threonine to alanine substitution at amino acid 877 (T877A), is a gain-of-function mutation. T877A can be activated by antiandrogens (e.g., flutamide), but also by steroid hormones (e.g., progesterone) that are precursors of androgen synthesis. It was also shown that when CYP17A1 is effectively inhibited (e.g., by abiraterone), intracellular progesterone levels increase and drive transcription of target genes in cells expressing the AR T877A mutant. Ultimately, this results in clones able to overcome abiraterone inhibition. One study demonstrated that the T877A mutant (referred to as T878A in this publication) was detected in 3 of 18 CRPC cases after abiraterone treatment. Another study showed that AR point mutations H874Y and T877A were detected in circulating cell-free DNA of 7 out of 29 patients resistant to abiraterone. That study also documented the high frequency (53%) of AR amplification occurring in cell-free DNA of patients progressing on enzalutamide, in comparison to abiraterone or other treatments. Accumulating data point to the emergence of AR point mutations as a mechanism of resistance to enzalutamide and abiraterone, and it remains to be shown whether the spectrum of mutations may be different for enzalutamide vs. abiraterone. Availability of noninvasive assays of CTCs or plasma DNA using high-throughput sequencing technologies may lead to greater precision in determining the mechanisms of resistance and allow for selection of more effective therapy for individual patients.

Preclinical studies of xenograft tumors have yielded additional hypotheses regarding mechanisms of resistance. The glucocorticoid receptor may bypass the need for AR, and in the context of potent AR inhibition, the glucocorticoid receptor is capable of activating a subset of AR target genes and promoting tumor progression. A gain-of-function mutation (N367T) in the enzyme 3β-hydroxysteroid dehydrogenase 1, involved in androgen biosynthesis, may allow increased synthesis of DHT from precursors and this mutation was found in a subset of xenograft tumors after exposure to abiraterone. Increased expression of the enzyme 17β-hydroxysteroid dehydrogenase (AKR1C3) was found in enzalutamide-resistant xenograft tumors. These data raise the possibility that an alternate steroid receptor or increased androgen biosynthesis may reactivate the AR signaling axis, or downstream targets, after exposure to abiraterone and enzalutamide.

**AGENTS IN DEVELOPMENT THAT OVERCOME SECONDARY AR RESISTANCE**

Despite the availability of enzalutamide and abiraterone for CRPC patients, secondary resistance mechanisms inevitably result in clinical progression. Galetore (formerly VN/124-I or TOK-001) and EPI-001 are two examples of novel compounds in development that target the AR and attempt to overcome issues related to secondary resistance to enzalutamide and/or abiraterone. Other antiandrogens in development (ARN-509 and ODM-201) have mechanisms of action similar to enzalutamide, and it is unclear how effectively these agents overcome resistance to abiraterone and/or enzalutamide.

Galetore (3β-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-diene) was originally developed as a CYP17A1 inhibitor, and is set to enter phase III clinical trials for CRPC. Galetore is a novel AR-targeting agent with a trimodal mechanism of action. Similar to abiraterone, galetore selectively and irreversibly inhibits CYP17A1 and prevents intratumoral androgen synthesis. However, galetore is pharmacologically distinct from abiraterone in its mechanisms of CYP17A1 inhibition. While abiraterone has been shown to be a potent inhibitor of 17α-hydroxylase and C17,20-lyase, galetore only inhibits the latter. Inhibition of C17,20-lyase effectively blocks the production of androgens, whereas inhibition of 17α-hydroxylase can lead to the overproduction of progesterone and pregnenalone and cause a secondary mineralocorticoid excess. Symptoms of mineralocorticoid overproduction include hypokalemia, hypertension, and fluid retention, all of which are abrogated by prednisone therapy. Clinically, this distinction is important because, as a selective inhibitor of C17,20-lyase, galetore (and other selective C17,20-lyase inhibitors, such as VT-464 and ODM-201) may be able to block the production of androgens without causing symptoms of secondary mineralocorticoid excess and thereby spare patients from concomitant corticosteroid therapy.

Galetore is also similar to enzalutamide because it is an AR antagonist and blocks androgenic ligand binding. However, galetore is distinct from either of its predecessors because it also
has the ability to degrade the AR and decrease AR levels (Figure 2). Additionally, galeterone has also been shown to impair AR binding to chromatin. ARMOR1 was a phase I dose escalation study that tested the safety of galeterone in chemotherapy-naïve CRPC patients with either metastatic or nonmetastatic disease (n = 49). This study revealed that galeterone was safe at all doses, and demonstrated activity in CRPC. Results from the phase II ARMOR2 trial (ClinicalTrials.gov Identifier: NCT01709734) (n = 52) revealed that 82% of patients with treatment-naïve CRPC had a 30% reduction in PSA, and 75% had a 50% reduction in PSA. Among ARMOR2 patients with abiraterone-refractory disease, 27% had reductions in PSA, and 13% had a 30% reduction in PSA. Six of 11 patients with treatment-naïve CRPC had high expression of AR splice variants containing the N-terminus of the AR and lacking the C-terminus. Five of these patients experienced at least a 50% reduction in PSA, suggesting that galeterone could still be effective in the treatment of CRPC clones positive for AR splice variants. Moreover, preclinical data have revealed that galeterone is able to effectively degrade AR-V7 splice variant receptors. Mechanisms by which galeterone (which presumably interacts with AR in the LBD region) induces AR-V7 degradation remain to be elucidated. In this context, it should be noted that CTCs expressing AR-V7 expressed high levels of full-length AR concomitantly. AR-V7 and full-length AR form a complex as a heterodimer. Galetore may target the full-length AR/AR-V7 complex for degradation, thereby effectively inhibiting the transcriptional activity of AR-V7. Because galeterone directly degrades the AR, including the AR-V7 splice variant, it may prove to be more effective than abiraterone and/or enzalutamide for AR-V7-positive patients. A randomized phase III trial (ARMOR3-SV) is planned to compare galeterone and enzalutamide in abiraterone or enzalutamide treatment-naïve mCRPC patients with AR-V7-positive circulating prostate cancer cells (ClinicalTrials.gov Identifier: NCT02438007). Upon completion of this trial, a separate trial of galeterone should be conducted in patients with detectable AR-V7 who have had previous exposure to an AR-targeting agent to determine the efficacy of galeterone in the context of secondary resistance. Preclinical research has also shown that galeterone is particularly effective against prostate cancer cells with the T877A AR mutation; however, this observation still requires further confirmation in human subjects.

Unlike previous antiandrogen therapies, a novel compound EPI-001 targets AR axis signaling by blocking the AR NTD. EPI-001 is a mixture of four stereoisomers and binds to the activation function-1 (AF-1) region of the AR NTD. Binding to the NTD is a unique mechanism in comparison to currently available AR-targeting agents because it can potentially bypass secondary resistance mechanisms associated with the loss of the AR LBD. EPI-001 has been shown to be an effective inhibitor of AR transcriptional activity and can inhibit transactivation of the AR NTD and block induction of androgen target genes. Through covalent binding of the NTD, EPI-001 reduced protein–protein interactions between AR and coregulators p300/CoBp, which are required for AR-mediated transactivation (Figure 2). Treatment with EPI-001 caused cytoceduction of CRPC xenografts dependent on AR for growth and survival without causing toxicity and reduced protein–protein interactions with the AR NTD. EPI-001 has also been shown to have a specificity for blocking AR-dependent growth of prostate cancer cells, while having no effect on the proliferation of cells that are not dependent on AR signaling for growth. But most important, EPI-001 has been shown to inhibit the transcriptional activity of the ARV567es splice variant. The ARV567es (variant 5, 6, 7 exon skipped) splice variant, like AR-V7, does not possess the AR LBD due to loss of exon 5–7. Therefore, it stands to reason that EPI-001 (or agents with similar mechanisms of action, such as EPI-506) would be effective in inhibiting the transcriptional activity of all AR-Vs, including AR-V7; however, preclinical and clinical studies are necessary to test this hypothesis. EPI-506 will be tested in a phase I/II trial of CRPC patients that is expected to be initiated in 2015.

CONCLUSIONS

Reactivation of the AR axis signaling, after initial ADT treatment, underlies progression to a CRPC phenotype for virtually all men diagnosed with PC. Better understanding of CRPC tumor biology, such as AR amplification/overexpression/alteration and intratumoral androgen synthesis, led to the introduction of two AR-targeting agents (abiraterone and enzalutamide) associated with increased survival and clinical benefit. However, the gain in survival is modest (3–4 months) and CRPC remains a terminal disease with a uniformly fatal outcome. Preclinical and clinical studies have revealed that several acquired resistance mechanisms result in AR pathway activation, including: AR splice variants lacking the LBD, missense point mutations in the AR, overexpression or mutation in androgen biosynthetic enzymes, and a glucocorticoid receptor that may possess the ability to bypass the AR. Clinical observation of increasing serum PSA levels as the early sign of treatment failure after abiraterone and enzalutamide is consistent with the idea that CRPC remains a disease driven by AR signaling. Therefore, efforts are under way to develop novel AR-targeting drugs that can overcome the development of resistance.

The AR-V7 splice variant may be the first predictive biomarker for patients with mCRPC that can be used to help inform clinicians regarding resistance and treatment. However, additional preclinical and clinical validation must be performed before AR-V7 can be implemented. First, independent and more robust clinical studies need to be performed to provide large-scale validation of previous clinical findings. Also, mechanistic data that provide the role of AR-V7 and full-length AR in drug resistance to abiraterone and/or enzalutamide are still needed. Collectively, these additional studies should help delineate whether AR-V7 is truly a predictive biomarker, or simply a marker of prognosis. The ARMOR3-SV trial undoubtedly will help elucidate the role of AR-V7 in primary resistance, but a second trial, which enrolls CRPC patients who have progressed on abiraterone and/or enzalutamide, is necessary to test AR-V7 as a predictive biomarker.

Furthermore, prospective clinical validation of missense point mutations in the AR is essential towards elucidating their role in mCRPC, in acquired resistance to abiraterone and enzalutamide,
and in the effectiveness of novel AR-targeting agents in development (e.g., galeterone and EPI-001/506). Moreover, clinical validation of these potentially predictive biomarkers may also aid in treatment selection for the subset of patients who will benefit from a particular novel AR-targeting agent once acquired resistance to abiraterone and/or enzalutamide has occurred. Finally, the elucidation of additional mechanisms of acquired resistance to AR-targeting drugs should be explored, both preclinically and clinically, to identify and validate additional informative predictive biomarkers. Biomarkers interrogating enzymes involved in androgen biosynthesis (e.g., 3β-hydroxysteroid dehydrogenase 1) and glucocorticoid receptor-mediated expression of AR target genes in the presence of AR inhibition could conceivably provide clinicians with an even greater number of predictive biomarkers that could be used during the treatment selection process.

Clearly, there is an urgent need for the continued development and FDA approval of novel AR-targeting agents that can be effective in the setting mCRPC with secondary resistance to AR axis signaling. Galeterone possesses many of the same mechanisms as both abiraterone and enzalutamide, but is distinct from its predecessors in its ability to degrade the AR and reduce AR levels. Galeterone has also been shown preclinically to be effective against clones with AR splice variants and missense point mutations. EPI-001 is a novel agent that targets the AR NTD, and is therefore not reliant on ligand binding to exert its effects on the AR. EPI-506 is currently entering clinical development. Collectively, this provides a rationale for the continued development of these agents to be used in mCRPC patients with demonstrated secondary resistance to abiraterone and/or enzalutamide. Moreover, additional clinical trials will help provide insights into timing, sequencing, and novel combinations for the treatment of mCRPC.

ACKNOWLEDGMENTS

The authors thank Dr. Lana Crona for help in reviewing and editing this review. D.J.C. was supported by T32GM086330 from the National Institute of General Medicine Sciences (NIGMS).

AUTHOR CONTRIBUTIONS

D.J.C., M.I.M, and Y.E.W. all contributed equally in the conception, writing, editing, and approval of this State of the Art review.

CONFLICTS OF INTEREST/DISCLOSURE

Y.E.W. received research funding from Astellas and Janssen and Tokai. M.I.M. received research funding from Janssen. D.J.C. states no conflicts of interest.

© 2015 American Society for Clinical Pharmacology and Therapeutics


